Janssen Pharmaceuticals Inc.

06/28/2024 | Press release | Archived content

Nipocalimab pivotal Phase 3 trial demonstrates longest sustained disease control in FcRn class for broadest population of myasthenia gravis patients

Read this content
Click here to read the original version at the source's official website. The text of this article is not available at the moment.